Previous 10 | Next 10 |
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Reata Pharmaceuticals, Inc. (RETA) Q3 2021 Financial Results and Update on Development Programs Conference Call November 8, 2021 8:30 AM ET Company Participants Warren Huff – Chief Executive Officer Colin Meyer – Chief Research and Development Officer Dawn Bir – Chief Com...
Shares of Reata Pharmaceuticals (NASDAQ:RETA) are up 6% in premarket trading after the company reported Q3 2021 earnings results that beat analyst estimates. The company's net loss widened ~10% to $71.8M (Loss of $1.97 per basic and diluted share.). On a GAAP basis, R&D expenses...
Reata Pharmaceuticals (NASDAQ:RETA): Q3 Non-GAAP EPS of -$1.27 beats by $0.62; GAAP EPS of -$1.97 beats by $0.22. Revenue of $7.39M (+427.9% Y/Y) beats by $5.32M. Press Release For further details see: Reata Pharmaceuticals EPS beats by $0.62, beats on revenue
Advisory Committee Meeting for Bardoxolone for Patients With CKD Caused by Alport Syndrome Scheduled for December 8, 2021 Submitted MAA to the EMA for Bardoxolone for Patients With CKD Caused by Alport Syndrome in October 2021 Planned NDA Submission for Omave...
DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial. Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and hum...
Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q3 earnings results on Monday, November 8th, before market open. The consensus EPS Estimate is -$1.89 (-44.3% Y/Y) and the consensus Revenue Estimate is $2.07M (+47.9% Y/Y). Over the last 2 years, RETA has beaten EPS estimates 38% o...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development progr...
Reata Pharmaceuticals (NASDAQ:RETA) announces submission of a Marketing Authorization Application (MAA) for bardoxolone methyl to the EMA for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome. The MAA submission is based on the efficacy and safety...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced its submission of a Marketing Authorization Application ( ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...